FDA Approved: GLIADEL — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for GLIADEL (carmustine) filed by Azurity Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• GLIADEL (Carmustine)

Snippet

SUPPL AP for GLIADEL (CARMUSTINE)